sulforaphane has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 7 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the underlying mechanisms of sulforaphane, a natural histone deacetylase (HDAC) inhibitor, in inhibiting triple negative breast cancer cells growth and the therapeutic effects of combination of sulforaphane and doxorubicin in TNBC treatment." | 7.88 | Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells. ( Cao, C; Huang, Y; Li, X; Liu, Y; Wang, F; Wang, S; Xia, Y; Yang, F, 2018) |
| "To study the underlying mechanisms of sulforaphane, a natural histone deacetylase (HDAC) inhibitor, in inhibiting triple negative breast cancer cells growth and the therapeutic effects of combination of sulforaphane and doxorubicin in TNBC treatment." | 3.88 | Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells. ( Cao, C; Huang, Y; Li, X; Liu, Y; Wang, F; Wang, S; Xia, Y; Yang, F, 2018) |
| "Sulforaphane was shown to increase the accumulation of doxorubicin in the nuclei of cancer cells, accompanied by inhibition of mitosis, without affecting the reactive oxygen species status of the cell." | 1.91 | Anticancer effect and safety of doxorubicin and nutraceutical sulforaphane liposomal formulation in triple-negative breast cancer (TNBC) animal model. ( Fronczyk, K; Mazur, M; Pogorzelska, A; Sigorski, D; Świtalska, M; Wietrzyk, J; Wiktorska, K, 2023) |
| "Sulforaphane (SFN) is a naturally occurring organosulfur compound found in cruciferous vegetables such as broccoli, brussels sprouts and cabbage." | 1.62 | Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis. ( Sharma, A; Sharma, S; Shrivastava, N; Sinha, S; Vora, J, 2021) |
| " This synergistic activity enables a considerable reduction in cytostatic dosage and an increase in cancer treatment efficiency." | 1.51 | In the triple-negative breast cancer MDA-MB-231 cell line, sulforaphane enhances the intracellular accumulation and anticancer action of doxorubicin encapsulated in liposomes. ( Chilmonczyk, Z; Krug, P; Mazur, M; Mielczarek, L; Milczarek, M; Wiktorska, K, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Pogorzelska, A | 1 |
| Mazur, M | 3 |
| Świtalska, M | 2 |
| Wietrzyk, J | 2 |
| Sigorski, D | 1 |
| Fronczyk, K | 1 |
| Wiktorska, K | 3 |
| Milczarek, M | 2 |
| Cierpiał, T | 1 |
| Kiełbasiński, P | 1 |
| Małecka-Giełdowska, M | 1 |
| Sinha, S | 2 |
| Patel, S | 1 |
| Athar, M | 1 |
| Vora, J | 2 |
| Chhabria, MT | 1 |
| Jha, PC | 1 |
| Shrivastava, N | 2 |
| Sharma, S | 1 |
| Sharma, A | 1 |
| Yang, F | 1 |
| Wang, F | 1 |
| Liu, Y | 1 |
| Wang, S | 1 |
| Li, X | 1 |
| Huang, Y | 1 |
| Xia, Y | 1 |
| Cao, C | 1 |
| Mielczarek, L | 1 |
| Krug, P | 1 |
| Chilmonczyk, Z | 1 |
| Burnett, JP | 1 |
| Lim, G | 1 |
| Li, Y | 1 |
| Shah, RB | 1 |
| Lim, R | 1 |
| Paholak, HJ | 1 |
| McDermott, SP | 1 |
| Sun, L | 1 |
| Tsume, Y | 1 |
| Bai, S | 1 |
| Wicha, MS | 1 |
| Sun, D | 1 |
| Zhang, T | 1 |
7 other studies available for sulforaphane and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Anticancer effect and safety of doxorubicin and nutraceutical sulforaphane liposomal formulation in triple-negative breast cancer (TNBC) animal model.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Carriers; Female; Humans; Liposomes; Mice; Models, Anim | 2023 |
An Organofluorine Isoselenocyanate Analogue of Sulforaphane Affects Antimetabolite 5-Fluorouracil's Anticancer Activity: A Perspective for New Combinatory Therapy in Triple-Negative Breast Cancer.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fl | 2023 |
Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study.
Topics: Apigenin; Cell Line, Tumor; Computer Simulation; Female; Humans; Isothiocyanates; Kaempferols; Molec | 2019 |
Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
Topics: Antigens, CD; Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; | 2021 |
Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proli | 2018 |
In the triple-negative breast cancer MDA-MB-231 cell line, sulforaphane enhances the intracellular accumulation and anticancer action of doxorubicin encapsulated in liposomes.
Topics: Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols | 2019 |
Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Prolifer | 2017 |